# US 2024/0390460 A1 · Antibody resistant modified receptors to enhance cell-based therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390460 A1
- Document ID: US20240390460A1
- Status: Published application
- Kind: A1
- Application number: 18/799,190
- Filed: 2024-08-09
- Published: 2024-11-28
- Earliest claimed: 2022-09-28
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Michael Moore; Casandra Panea; Matthew Sleeman; Andrew J. Murphy; George D. Yancopoulos; Liang Zhang; Annabel Romero Hernández
- Web page: https://patentgrep.com/patent/US20240390460A1

## CPC

- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/13: B-cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/35: Cytokines
- A61P 35/00: Antineoplastic agents
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 5/0636: {T lymphocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- A61K 40/42: Cancer antigens
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subunit gamma (IL2RG)) that is functionally indistinguishable but immunologically distinguishable from a second isoform of the target protein, administering the donor cells to the subject, and then selectively inhibiting host cells in the subject based on their expression of the second isoform of the target protein, thereby improving engraftment of donor cells in the subject. Also provided are combinations for administration to a subject in need thereof, wherein the combination comprises (1) a population of donor cells modified to express a first isoform of a target protein (e.g., IL2RG) and (2) an antagonist (e.g., anti-IL2RG antigen-binding protein) that specifically binds to a second isoform of the target protein but does not specifically bind to the first isoform of the target protein.

## Claims

### Claim 1

A method for improving engraftment of donor cells in a subject in need thereof, comprising:
(a) providing donor cells that have been modified to express a first isoform of a target protein, wherein the target protein is a protein expressed on the cell surface of hematopoietic cells, wherein the first isoform of the target protein is different from a second isoform of the target protein, wherein the second isoform is expressed in host cells of the subject;
(b) administering the donor cells to the subject, and
(c) selectively inhibiting host cells in the subject based on their expression of the second isoform of the target protein, thereby improving engraftment of donor cells in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target protein is a receptor.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the target protein is a cytokine receptor or a chemokine receptor, optionally wherein the target protein is the cytokine receptor.

### Claim 4

The method of any preceding claim, wherein the target protein is a protein expressed on the cell surface of lymphocytes.

### Claim 5

The method of any preceding claim, wherein the target protein is a cytokine receptor sub-unit of an interleukin-2 (IL-2) receptor, an IL-4 receptor, an IL-7 receptor, an IL-9 receptor, an IL-15 receptor, or an IL-21 receptor.

### Claim 6

The method of any preceding claim, wherein the target protein is interleukin-2 receptor subunit gamma (IL2RG).

### Claim 7

The method of any preceding claim, wherein the selective inhibition of host cells in step (c) does not comprise ablation of host cells by an active killing mechanism.

### Claim 8

The method of any preceding claim, wherein the selective inhibition in step (c) comprises: (1) blocking growth of the host cells to provide a competitive growth advantage to the donor cells; (2) blocking localization or trafficking of the host cells to provide a competitive homing advantage to the donor cells; (3) blocking a cell-cell interaction or adhesion of the host cells to provide a competitive tissue infiltration advantage to the donor cells; or (4) blocking immune cell activation in the host cells to provide a competitive advantage to the donor cells.

### Claim 9

The method of any preceding claim, wherein the selective inhibition in step (c) comprises blocking growth of the host cells and/or blocking immune cell activation in the host cells to provide a competitive growth advantage to the donor cells.

### Claim 10

The method of any preceding claim, wherein the first isoform and the second isoform are functionally indistinguishable but immunologically distinguishable.

### Claim 11

The method of any preceding claim, wherein the donor cells express both the first isoform of the target protein and the second isoform of the target protein.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the donor cells express only the first isoform of the target protein.

### Claim 13

The method of any preceding claim, wherein the first isoform of the target protein is expressed from an expression vector in the donor cells, or wherein a genomic locus has been edited to express the first isoform of the target protein in the donor cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the genomic locus is an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG and the genomic locus is an IL2RG genomic locus.

### Claim 15 (depends on 13)

The method of claim 13, wherein the genomic locus is not an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG, and the genomic locus is not an IL2RG genomic locus.

### Claim 16

The method of any preceding claim, wherein the first isoform of the target protein is a genetically engineered isoform of the target protein.

### Claim 17

The method of any preceding claim, wherein the first isoform of the target protein is genetically engineered to comprise a mutation to provide an altered epitope, optionally wherein the mutation is an artificial mutation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the altered epitope is a binding region of a target protein antagonist such that the target protein antagonist exhibits reduced or abolished ability to bind and/or inhibit the first isoform of the target protein compared to its ability to bind and/or inhibit the second isoform of the target protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein both the first isoform of the target protein and the second isoform of the target protein retain the ability to bind to an endogenous ligand, optionally wherein the target protein antagonist blocks the binding of the endogenous ligand to the second isoform of the target protein but not the first isoform of the target protein.

### Claim 20 (depends on 18, 19)

The method claim 18 or 19, wherein the target protein is IL2RG,
wherein the altered epitope is in a binding region of the target protein antagonist, wherein the target protein antagonist is an antibody comprising an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation encoded by nucleotides within exon 2 and/or exon 3 of the IL2RG gene at the IL2RG genomic locus.

### Claim 22 (depends on 17, 18, 19, 20, 21)

The method of any one of claims 17-21, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution within a region from position T127 to position N150 and/or within a region from position L87 to position D97.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The method of any one of claims 17-22, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145, position W90, position K92, position N93, position D95, position D97, position T127, position R139, position R140, position Q141, position T143, and/or position K147.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 17-23, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145, optionally wherein the substitution is a M145K substitution, a M145D substitution, a M145E substitution, a M145P substitution, a M145W substitution, or an M145Y substitution.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 17-24, wherein the target protein is IL2RG, and wherein the mutation comprises a M145K substitution.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 17-25, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position W90, optionally wherein the substitution is a W90V substitution, a W90R substitution, a W90Q substitution, a W90L substitution, a W90K substitution, a W90E substitution, or a W90D substitution, optionally wherein the mutation comprises a W90Q substitution.

### Claim 27 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 17-26, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145 and a mutation or substitution at position W90.

### Claim 28

The method of any preceding claim, wherein the selective inhibition in step (c) comprises administering a target protein antagonist to the subject, wherein the target protein antagonist specifically binds to the second isoform of the target protein but does not specifically bind to the first isoform of the target protein, optionally wherein step (c) comprises multiple administrations of the target protein antagonist.

### Claim 29 (depends on 18, 19, 20, 28)

The method of any one of claims 18-20 and 28, wherein the target protein antagonist is an antigen-binding protein.

### Claim 30 (depends on 29)

The method of claim 29, wherein the antigen-binding protein is an antibody or an antigen-binding fragment thereof.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 32 (depends on 31)

The method of claim 31,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 33 (depends on 29, 30)

The method of claim 29 or 30, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 10, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 2.

### Claim 34 (depends on 33)

The method of claim 33, wherein the target protein is IL2RG,
wherein the immunoglobulin light chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 10, and
wherein the immunoglobulin heavy chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 2.

### Claim 35

The method of 29 or 30, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 20, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 18.

### Claim 36

The method of any preceding claim, wherein the donor cells and/or the host cells are hematopoietic cells, optionally wherein the donor cells and/or the host cells are immune cells.

### Claim 37

The method of any preceding claim, wherein the donor cells and/or the host cells are lymphocytes or lymphoid progenitor cells.

### Claim 38

The method of any preceding claim, wherein the donor cells and/or the host cells are T cells.

### Claim 39

The method of any preceding claim, wherein the donor cells and/or the host cells are tumor infiltrating lymphocytes (TILs).

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the donor cells and/or the host cells are B cells.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the donor cells and/or the host cells are NK cells.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the donor cells and/or the host cells are hematopoietic stem and progenitor cells.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the donor cells and/or the host cells are derived from hematopoietic stem cells or hematopoietic stem and progenitor cells.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the donor cells are derived from induced pluripotent stem cells.

### Claim 45

The method of any preceding claim, wherein the subject is a mammal or a non-human mammal, and the donor cells are mammalian cells or non-human mammalian cells.

### Claim 46

The method of any preceding claim, wherein the subject is a human, and the donor cells are human cells.

### Claim 47

The method of any preceding claim, wherein the donor cells comprise or express a therapeutic molecule.

### Claim 48 (depends on 47)

The method of claim 47, wherein the therapeutic molecule does not target the target protein.

### Claim 49

The method of any preceding claim, wherein the donor cells comprise or express an immunoglobulin.

### Claim 50 (depends on 49)

The method of claim 49, wherein the immunoglobulin does not target the target protein.

### Claim 51

The method of any preceding claim, wherein the donor cells comprise a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).

### Claim 52 (depends on 51)

The method of claim 51, wherein the CAR or the exogenous TCR does not target the target protein.

### Claim 53

The method of any preceding claim, wherein the donor cells are autologous.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1-52, wherein the donor cells are allogeneic or syngeneic.

### Claim 55

The method of any preceding claim, wherein the subject has a disease or disorder, and the method is for treating the disease or disorder.

### Claim 56

The method of any preceding claim, wherein the subject has cancer.

### Claim 57 (depends on 56)

The method of claim 56, wherein the cancer is a solid tumor cancer.

### Claim 58 (depends on 56)

The method of claim 56, wherein the cancer is a hematologic cancer.

### Claim 59

The method of any preceding claim, wherein the subject has a hematopoietic malignancy, and the method is for treating the hematopoietic malignancy in the subject.

### Claim 60

The method of any preceding claim, wherein the subject has defective immune cells or a genetic deficiency in hematopoiesis.

### Claim 61 (depends on 60)

The method of claim 60, wherein the genetic deficiency in hematopoiesis is sickle cell disease or severe combined immunodeficiency (SCID).

### Claim 62

The method of any preceding claim, wherein steps (b) and (c) occur simultaneously.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1-61, wherein step (b) occurs prior to step (c), optionally wherein step (c) comprises multiple administrations of a target protein antagonist subsequent to step (b).

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1-61, wherein step (b) occurs subsequent to step (c), optionally wherein step (c) comprises multiple administrations of a target protein antagonist prior to step (b).

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein step (c) occurs both prior to and subsequent to step (b), optionally wherein step (c) comprises multiple administrations of a target protein antagonist prior to step (b) and/or multiple administrations of the target protein antagonist subsequent to step (b).

### Claim 66

The method of any preceding claim, further comprising generating the donor cells by modifying a population of cells to express the first isoform of the target protein prior to step (a).

### Claim 67 (depends on 66)

The method of claim 66, wherein the population of cells is a population of induced pluripotent stem cells, and the method further comprises differentiating the induced pluripotent stem cells prior to step (a) into the donor cells that are administered in step (a), optionally wherein the induced pluripotent stem cells are differentiated into hematopoietic cells, lymphocytes or lymphoid progenitor cells, T cells, B cells, NK cells, hematopoietic stem cells, or hematopoietic stem and progenitor cells.

### Claim 68 (depends on 66)

The method of claim 66, wherein the population of cells is a population of hematopoietic stem cells or hematopoietic stem and progenitor cells, and the method further comprises differentiating the hematopoietic stem cells or hematopoietic stem and progenitor cells prior to step (a) into the donor cells that are administered in step (a), optionally wherein the hematopoietic stem cells or hematopoietic stem and progenitor cells are differentiated into differentiated hematopoietic cells, lymphocytes or lymphoid progenitor cells, T cells, B cells, or NK cells.

### Claim 69 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein generating the donor cells comprises introducing an expression vector encoding the first isoform of the target protein to express the first isoform of the target protein prior to step (a), or wherein generating the donor cells comprises editing a genomic locus in the population of cells to express the first isoform of the target protein prior to step (a).

### Claim 70 (depends on 69)

The method of claim 69, wherein the genomic locus is an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG, and the genomic locus is an IL2RG genomic locus.

### Claim 71 (depends on 69)

The method of claim 69, wherein the genomic locus is not an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG, and the genomic locus is not an IL2RG genomic locus.

### Claim 72 (depends on 69, 70, 71)

The method of any one of claims 69-71, wherein the editing comprises introducing into the population of cells:
(1) a nuclease agent or one or more nucleic acids encoding the nuclease agent, wherein the nuclease agent targets a nuclease target sequence in the genomic locus; and
(2) an exogenous donor nucleic acid,
wherein the nuclease agent cleaves the genomic locus and the exogenous donor nucleic acid is inserted into the genomic locus or recombines with the genomic locus to generate the donor cells that express the first isoform of the target protein.

### Claim 73 (depends on 72)

The method of claim 72, wherein the nuclease agent comprises:
(a) a zinc finger nuclease (ZFN);
(b) a transcription activator-like effector nuclease (TALEN); or
(c) (i) a Cas protein; and
(ii) a guide RNA, wherein the guide RNA comprises a DNA-targeting segment that targets a guide RNA target sequence that is the nuclease target sequence, and wherein the guide RNA binds to the Cas protein and targets the Cas protein to the guide RNA target sequence.

### Claim 74 (depends on 73)

The method of claim 73, wherein the nuclease agent comprises the Cas protein and the guide RNA, optionally wherein the DNA-targeting segment comprises the sequence set forth in any one of SEQ ID NOS: 76-87 or the guide RNA target sequence comprises the sequence set forth in any one of SEQ ID NOS: 64-75, or optionally wherein the DNA-targeting segment comprises the sequence set forth in any one of SEQ ID NOS: 136-153 or the guide RNA target sequence comprises the sequence set forth in any one of SEQ ID NOS:
118-135.

### Claim 75 (depends on 73, 74)

The method of claim 73 or 74, wherein the Cas protein is a Cas9 protein.

### Claim 76 (depends on 72, 73, 74, 75)

The method of any one of claims 72-75, wherein the exogenous donor nucleic acid comprises homology arms.

### Claim 77 (depends on 72, 73, 74, 75, 76)

The method of any one of claims 72-76, wherein the exogenous donor nucleic acid is a single-stranded oligodeoxynucleotide (ssODN), optionally wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 88-117 or optionally wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 154-173.

### Claim 78 (depends on 77)

The method of claim 77, wherein:
(I) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 77 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 65, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 88-97;
(II) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 83 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 71, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 98-107;
(III) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 86 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 74, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 108-117;
(IV) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 137 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 119, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 154-163; or
(V) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 138 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 120, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 164-173.

### Claim 79 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 66-78, further comprising isolating the population of cells from the subject or from a different subject prior to modifying the population of cells.

### Claim 80

A combination medicament for administration to a subject in need thereof, comprising:
(a) a population of donor cells modified to express a first isoform of a target protein, wherein the target protein is a protein expressed on the cell surface of hematopoietic cells, wherein the first isoform of the target protein is different from a second isoform of the target protein; and
(b) a target protein antagonist that specifically binds to the second isoform of the target protein but does not specifically bind to the first isoform of the target protein.

### Claim 81 (depends on 80)

The combination medicament of claim 80, wherein the target protein is a receptor.

### Claim 82 (depends on 80, 81)

The combination medicament of claim 80 or 81, wherein the target protein is a cytokine receptor or a chemokine receptor, optionally wherein the target protein is the cytokine receptor.

### Claim 83 (depends on 80, 81, 82)

The combination medicament of any one of claims 80-82, wherein the target protein is a protein expressed on the cell surface of lymphocytes.

### Claim 84 (depends on 80, 81, 82, 83)

The combination medicament of any one of claims 80-83, wherein the target protein is a cytokine receptor sub-unit of an interleukin-2 (IL-2) receptor, an IL-4 receptor, an IL-7 receptor, an IL-9 receptor, an IL-15 receptor, or an IL-21 receptor.

### Claim 85 (depends on 80, 81, 82, 83, 84)

The combination medicament of any one of claims 80-84, wherein the target protein is interleukin-2 receptor subunit gamma (IL2RG).

### Claim 86 (depends on 80, 81, 82, 83, 84, 85)

The combination medicament of any one of claims 80-85, wherein the target protein antagonist selectively inhibits host cells in the subject based on their expression of the second isoform of the target protein.

### Claim 87 (depends on 86)

The combination medicament of claim 86, wherein the selective inhibition of host cells does not comprise ablation of host cells by an active killing mechanism.

### Claim 88 (depends on 86, 87)

The combination medicament of claim 86 or 87, wherein the selective inhibition comprises: (1) blocking growth of the host cells to provide a competitive growth advantage to the donor cells; (2) blocking localization or trafficking of the host cells to provide a competitive homing advantage to the donor cells; (3) blocking a cell-cell interaction or adhesion of the host cells to provide a competitive tissue infiltration advantage to the donor cells; or (4) blocking immune cell activation in the host cells to provide a competitive advantage to the donor cells.

### Claim 89 (depends on 86, 87, 88)

The combination medicament of any one of claims 86-88, wherein the selective inhibition comprises blocking growth of the host cells and/or blocking immune cell activation in the host cells to provide a competitive growth advantage to the donor cells.

### Claim 90 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The combination medicament of any one of claims 80-89, wherein the first isoform and the second isoform are functionally indistinguishable but immunologically distinguishable.

### Claim 91 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The combination medicament of any one of claims 80-90, wherein the donor cells express both the first isoform of the target protein and the second isoform of the target protein.

### Claim 92 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The combination medicament of any one of claims 80-90, wherein the donor cells express only the first isoform of the target protein.

### Claim 93 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The combination medicament of any one of claims 80-92, wherein the first isoform of the target protein is expressed from an expression vector in the population of donor cells, or wherein a genomic locus has been edited to express the first isoform of the target protein in the population of donor cells.

### Claim 94 (depends on 93)

The combination medicament of claim 93, wherein the genomic locus is an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG, and the genomic locus is an IL2RG genomic locus.

### Claim 95 (depends on 93)

The combination medicament of claim 93, wherein the genomic locus is not an endogenous genomic locus encoding the target protein, optionally wherein the target protein is IL2RG, and the genomic locus is not an IL2RG genomic locus.

### Claim 96 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The combination medicament of any one of claims 80-95, wherein the first isoform of the target protein is a genetically engineered isoform of the target protein.

### Claim 97 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The combination medicament of any one of claims 80-96, wherein the first isoform of the target protein is genetically engineered to comprise a mutation to provide an altered epitope, optionally wherein the mutation is an artificial mutation.

### Claim 98 (depends on 97)

The combination medicament of claim 97, wherein the altered epitope is a binding region of the target protein antagonist such that the target protein antagonist exhibits reduced or abolished ability to bind and/or inhibit the first isoform of the target protein compared to its ability to bind and/or inhibit the second isoform of the target protein.

### Claim 99 (depends on 98)

The combination medicament of claim 98, wherein both the first isoform of the target protein and the second isoform of the target protein retain the ability to bind to an endogenous ligand, optionally wherein the target protein antagonist blocks the binding of the endogenous ligand to the second isoform of the target protein but not the first isoform of the target protein.

### Claim 100 (depends on 97, 98, 99)

The combination medicament of any one of claims 97-99, wherein the target protein is IL2RG,
wherein the altered epitope is in a binding region of the target protein antagonist, wherein the target protein antagonist is an antibody comprising an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 101 (depends on 97, 98, 99, 100)

The combination medicament of any one of claims 97-100, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation encoded by nucleotides within exon 2 and/or exon 3 of the IL2RG gene at the IL2RG genomic locus.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The combination medicament of any one of claims 97-101, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution within a region from position T127 to position N150 and/or within a region from position L87 to position D97.

### Claim 103 (depends on 97, 98, 99, 100, 101, 102)

The combination medicament of any one of claims 97-102, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145, position W90, position K92, position N93, position D95, position D97, position T127, position R139, position R140, position Q141, position T143, and/or position K147.

### Claim 104 (depends on 97, 98, 99, 100, 101, 102, 103)

The combination medicament of any one of claims 97-103, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145, optionally wherein the substitution is a M145K substitution, a M145D substitution, a M145E substitution, a M145P substitution, a M145W substitution, or an M145Y substitution.

### Claim 105 (depends on 97, 98, 99, 100, 101, 102, 103, 104)

The combination medicament of any one of claims 97-104, wherein the target protein is IL2RG, and wherein the mutation comprises a M145K substitution.

### Claim 106 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105)

The combination medicament of any one of claims 97-105, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position W90, optionally wherein the substitution is a W90V substitution, a W90R substitution, a W90Q substitution, a W90L substitution, a W90K substitution, a W90E substitution, or a W90D substitution, optionally wherein the mutation comprises a W90Q substitution.

### Claim 107 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The combination medicament of any one of claims 97-106, wherein the target protein is IL2RG, and wherein the mutation comprises a mutation or substitution at position M145 and a mutation or substitution at position W90.

### Claim 108 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The combination medicament of any one of claims 80-107, wherein the target protein antagonist is an antigen-binding protein.

### Claim 109 (depends on 108)

The combination medicament of claim 108, wherein the antigen-binding protein is an antibody or an antigen-binding fragment thereof.

### Claim 110 (depends on 108, 109)

The combination medicament of claim 108 or 109, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 111 (depends on 110)

The combination medicament of claim 110,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 112 (depends on 108, 109)

The combination medicament of claim 108 or 109, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 10, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 2.

### Claim 113 (depends on 112)

The combination medicament of claim 112, wherein the target protein is IL2RG,
wherein the immunoglobulin light chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 10, and
wherein the immunoglobulin heavy chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 2.

### Claim 114 (depends on 108, 109)

The combination medicament of claim 108 or 109, wherein the target protein is IL2RG,
wherein the antigen-binding protein comprises an immunoglobulin light chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 20, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 18.

### Claim 115 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The combination medicament of any one of claims 80-114, wherein the donor cells are hematopoietic cells, optionally wherein the donor cells are immune cells.

### Claim 116 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The combination medicament of any one of claims 80-115, wherein the donor cells are lymphocytes or lymphoid progenitor cells.

### Claim 117 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The combination medicament of any one of claims 80-116, wherein the donor cells are T cells.

### Claim 118 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The combination medicament of any one of claims 80-117, wherein the donor cells are tumor infiltrating lymphocytes (TILs).

### Claim 119 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The combination medicament of any one of claims 80-116, wherein the donor cells are B cells.

### Claim 120 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The combination medicament of any one of claims 80-116, wherein the donor cells are NK cells.

### Claim 121 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The combination medicament of any one of claims 80-115, wherein the donor cells are hematopoietic stem cells or hematopoietic stem and progenitor cells.

### Claim 122 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The combination medicament of any one of claims 80-121, wherein the donor cells are derived from induced pluripotent stem cells or are derived from hematopoietic stem cells or hematopoietic stem and progenitor cells.

### Claim 123 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

The combination medicament of any one of claims 80-122, wherein the subject is a mammal or a non-human mammal, and the donor cells are mammalian cells or non-human mammalian cells.

### Claim 124 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The combination medicament of any one of claims 80-123, wherein the subject is a human, and the donor cells are human cells.

### Claim 125 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The combination medicament of any one of claims 80-124, wherein the donor cells comprise or express a therapeutic molecule.

### Claim 126 (depends on 125)

The combination medicament of claim 125, wherein the therapeutic molecule does not target the target protein.

### Claim 127 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

The combination medicament of any one of claims 80-126, wherein the donor cells comprise or express an immunoglobulin.

### Claim 128 (depends on 127)

The combination medicament of claim 127, wherein the immunoglobulin does not target the target protein.

### Claim 129 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The combination medicament of any one of claims 80-128, wherein the donor cells comprise a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).

### Claim 130 (depends on 129)

The combination medicament of claim 129, wherein the CAR or the exogenous TCR does not target the target protein.

### Claim 131 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The combination medicament of any one of claims 80-130, wherein the donor cells are autologous.

### Claim 132 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The combination medicament of any one of claims 80-130, wherein the donor cells are allogeneic or syngeneic.

### Claim 133 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The combination medicament of any one of claims 80-132, wherein the subject has a disease or disorder, and the combination medicament is for treating the disease or disorder.

### Claim 134 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The combination medicament of any one of claims 80-133, wherein the subject has cancer.

### Claim 135 (depends on 134)

The combination medicament of claim 134, wherein the cancer is a solid tumor cancer.

### Claim 136 (depends on 134)

The combination medicament of claim 134, wherein the cancer is a hematologic cancer.

### Claim 137 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The combination medicament of any one of claims 80-132, wherein the subject has a hematopoietic malignancy, and the combination medicament is for treating the hematopoietic malignancy in the subject.

### Claim 138 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137)

The combination medicament of any one of claims 80-137, wherein the subject has defective immune cells or a genetic deficiency in hematopoiesis.

### Claim 139 (depends on 138)

The combination medicament of claim 138, wherein the genetic deficiency in hematopoiesis is sickle cell disease or severe combined immunodeficiency (SCID).

### Claim 140

An isolated cell or population of cells modified to express a first isoform of interleukin-2 receptor subunit gamma (IL2RG) that is different from a second isoform of IL2RG, wherein the first isoform of IL2RG is genetically engineered to comprise a mutation to provide an altered epitope, wherein the altered epitope is a binding region of an IL2RG antagonist such that the IL2RG antagonist exhibits reduced or abolished ability to bind and/or inhibit the first isoform of IL2RG compared to its ability to bind and/or inhibit the second isoform of IL2RG, and wherein the first isoform of IL2RG retains binding to its endogenous ligands.

### Claim 141 (depends on 140)

The isolated cell or population of cells of claim 140, wherein the mutation is an artificial mutation.

### Claim 142 (depends on 140, 141)

The isolated cell or population of cells of claim 140 or 141, wherein both the first isoform of IL2RG and the second isoform of IL2RG retain the ability to bind to an endogenous ligand, optionally wherein the IL2RG antagonist blocks the binding of the endogenous ligand to the second isoform of IL2RG but not the first isoform of IL2RG.

### Claim 143 (depends on 140, 141, 142)

The isolated cell or population of cells of any one of claims 140-142, wherein the first isoform and the second isoform are functionally indistinguishable but immunologically distinguishable.

### Claim 144 (depends on 140, 141, 142, 143)

The isolated cell or population of cells of any one of claims 140-143, wherein the cell or cells express both the first isoform of IL2RG and the second isoform of IL2RG.

### Claim 145 (depends on 140, 141, 142, 143)

The isolated cell or population of cells of any one of claims 140-143, wherein the cell or cells express only the first isoform of IL2RG.

### Claim 146 (depends on 140, 141, 142, 143, 144, 145)

The isolated cell or population of cells of any one of claims 140-145, wherein the first isoform of IL2RG is expressed from an expression vector in the cell or cells, or wherein a genomic locus has been edited to express the first isoform of IL2RG in the cell or cells.

### Claim 147 (depends on 146)

The isolated cell or population of cells of claim 146, wherein the genomic locus is an endogenous IL2RG genomic locus.

### Claim 148 (depends on 146)

The isolated cell or population of cells of claim 146, wherein the genomic locus is not an endogenous IL2RG genomic locus.

### Claim 149 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148)

The isolated cell or population of cells of any one of claims 140-148, wherein the altered epitope is in a binding region of the IL2RG antagonist, wherein the IL2RG antagonist is an antibody comprising an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 150 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149)

The isolated cell or population of cells of any one of claims 140-149, wherein the mutation comprises a mutation encoded by nucleotides within exon 2 and/or exon 3 of the IL2RG gene at the IL2RG genomic locus.

### Claim 151 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150)

The isolated cell or population of cells of any one of claims 140-150, wherein the mutation comprises a mutation or substitution within a region from position T127 to position N150 and/or within a region from position L87 to position D97.

### Claim 152 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151)

The isolated cell or population of cells of any one of claims 140-151, wherein the mutation comprises a mutation or substitution at position M145, position W90, position K92, position N93, position D95, position D97, position T127, position R139, position R140, position Q141, position T143, and/or position K147.

### Claim 153 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152)

The isolated cell or population of cells of any one of claims 140-152, wherein the mutation comprises a mutation or substitution at position M145, optionally wherein the substitution is a M145K substitution, a M145D substitution, a M145E substitution, a M145P substitution, a M145W substitution, or an M145Y substitution.

### Claim 154 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The isolated cell or population of cells of any one of claims 140-153, wherein the mutation comprises a M145K substitution.

### Claim 155 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

The isolated cell or population of cells of any one of claims 140-154, wherein the mutation comprises a mutation or substitution at position W90, optionally wherein the substitution is a W90V substitution, a W90R substitution, a W90Q substitution, a W90L substitution, a W90K substitution, a W90E substitution, or a W90D substitution, optionally wherein the mutation comprises a W90Q substitution.

### Claim 156 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The isolated cell or population of cells of any one of claims 140-155, wherein the mutation comprises a mutation or substitution at position M145 and a mutation or substitution at position W90.

### Claim 157 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156)

The isolated cell or population of cells of any one of claims 140-156, wherein the first isoform of IL2RG and the second isoform of IL2RG are immunologically distinguishable by the IL2RG antagonist, wherein the IL2RG antagonist specifically binds to the second isoform of IL2RG but does not specifically bind to the first isoform of IL2RG.

### Claim 158 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

The isolated cell or population of cells of any one of claims 140-157, wherein the IL2RG antagonist is an antigen-binding protein.

### Claim 159 (depends on 158)

The isolated cell or population of cells of claim 158, wherein the antigen-binding protein is an antibody or an antigen-binding fragment thereof.

### Claim 160 (depends on 158, 159)

The isolated cell or population of cells of claim 158 or 159, wherein the antigen-binding protein comprises an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 161 (depends on 160)

The isolated cell or population of cells of claim 160, wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 162 (depends on 158, 159)

The isolated cell or population of cells of claim 158 or 159, wherein the antigen-binding protein comprises an immunoglobulin light chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 10, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 2.

### Claim 163 (depends on 162)

The isolated cell or population of cells of claim 162, wherein the immunoglobulin light chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 10, and
wherein the immunoglobulin heavy chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 2.

### Claim 164 (depends on 158, 159)

The isolated cell or population of cells of claim 158 or 159, wherein the antigen-binding protein comprises an immunoglobulin light chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 20, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 18.

### Claim 165 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164)

The isolated cell or population of cells of any one of claims 140-164, wherein the cell or cells are hematopoietic cell(s), optionally wherein the cell or cells are immune cell(s).

### Claim 166 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165)

The isolated cell or population of cells of any one of claims 140-165, wherein the cell or cells are lymphocytes or lymphoid progenitor cell(s).

### Claim 167 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The isolated cell or population of cells of any one of claims 140-166, wherein the cell or cells are T cell(s).

### Claim 168 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167)

The isolated cell or population of cells of any one of claims 140-167, wherein the cell or cells are tumor infiltrating lymphocyte(s) (TILs).

### Claim 169 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The isolated cell or population of cells of any one of claims 140-166, wherein the cell or cells are B cell(s).

### Claim 170 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The isolated cell or population of cells of any one of claims 140-166, wherein the cell or cells are NK cell(s).

### Claim 171 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165)

The isolated cell or population of cells of any one of claims 140-165, wherein the cell or cells are hematopoietic stem cell(s) or hematopoietic stem and progenitor cell(s).

### Claim 172 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171)

The isolated cell or population of cells of any one of claims 140-171, wherein the cell or cells are induced pluripotent stem cell(s).

### Claim 173 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The isolated cell or population of cells of any one of claims 140-172, wherein the cell or cells are mammalian cell(s) or non-human mammalian cell(s).

### Claim 174 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The isolated cell or population of cells of any one of claims 140-173, wherein the cell or cells are human cell(s).

### Claim 175 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174)

The isolated cell or population of cells of any one of claims 140-174, wherein the cell or cells comprise or express a therapeutic molecule.

### Claim 176 (depends on 175)

The isolated cell or population of cells of claim 175, wherein the therapeutic molecule does not target IL2RG.

### Claim 177 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The isolated cell or population of cells of any one of claims 140-176, wherein the cell or cells comprise or express an immunoglobulin.

### Claim 178 (depends on 177)

The isolated cell or population of cells of claim 177, wherein the immunoglobulin does not target IL2RG.

### Claim 179 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The isolated cell or population of cells of any one of claims 140-178, wherein the cell or cells comprise a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).

### Claim 180 (depends on 179)

The isolated cell or population of cells of claim 179, wherein the CAR or the exogenous TCR does not target IL2RG.

### Claim 181 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The isolated cell or population of cells of any one of claims 140-180, wherein the cell or cells are isolated from a subject.

### Claim 182 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The isolated cell or population of cells of any one of claims 140-181 for use in treatment of a subject having cells expressing the second isoform of IL2RG.

### Claim 183 (depends on 182)

The isolated cell or population of cells for use of claim 182, wherein the cell or cells are isolated from the subject.

### Claim 184 (depends on 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

A method of making the isolated cell or population of cells of any one of claims 140-183, comprising modifying a cell or population of cells to express the first isoform of IL2RG.

### Claim 185 (depends on 184)

The method of claim 184, wherein the modifying comprises introducing an expression vector encoding the first isoform of IL2RG, or wherein the modifying comprises editing a genomic locus to express the first isoform of IL2RG.

### Claim 186 (depends on 185)

The method of claim 185, wherein the genomic locus is an endogenous IL2RG genomic locus.

### Claim 187 (depends on 185)

The method of claim 185, wherein the genomic locus is not an endogenous IL2RG genomic locus.

### Claim 188 (depends on 185, 186, 187)

The method of any one of claims 185-187, wherein the editing comprises introducing into the cells:
(1) a nuclease agent or one or more nucleic acids encoding the nuclease agent, wherein the nuclease agent targets a nuclease target sequence in the genomic locus; and
(2) an exogenous donor nucleic acid,
wherein the nuclease agent cleaves the genomic locus and the exogenous donor nucleic acid is inserted into the genomic locus or recombines with the genomic locus to generate the donor cells that express the first isoform of IL2RG.

### Claim 189 (depends on 188)

The method of claim 188, wherein the nuclease agent comprises:
(a) a zinc finger nuclease (ZFN);
(b) a transcription activator-like effector nuclease (TALEN); or
(c) (i) a Cas protein; and
(ii) a guide RNA, wherein the guide RNA comprises a DNA-targeting segment that targets a guide RNA target sequence that is the nuclease target sequence, and wherein the guide RNA binds to the Cas protein and targets the Cas protein to the guide RNA target sequence.

### Claim 190 (depends on 189)

The method of claim 189, wherein the nuclease agent comprises the Cas protein and the guide RNA, optionally wherein the DNA-targeting segment comprises the sequence set forth in any one of SEQ ID NOS: 76-87 or the guide RNA target sequence comprises the sequence set forth in any one of SEQ ID NOS: 64-75, or optionally wherein the DNA-targeting segment comprises the sequence set forth in any one of SEQ ID NOS: 136-153 or the guide RNA target sequence comprises the sequence set forth in any one of SEQ ID NOS:
118-135.

### Claim 191 (depends on 189, 190)

The method of claim 189 or 190, wherein the Cas protein is a Cas9 protein.

### Claim 192 (depends on 188, 189, 190, 191)

The method of any one of claims 188-191, wherein the exogenous donor nucleic acid comprises homology arms.

### Claim 193 (depends on 188, 189, 190, 191, 192)

The method of any one of claims 188-192, wherein the exogenous donor nucleic acid is a single-stranded oligodeoxynucleotide (ssODN), optionally wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 88-117 or optionally wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 154-173.

### Claim 194 (depends on 193)

The method of claim 193, wherein:
(I) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 77 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 65, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 88-97;
(II) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 83 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 71, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 98-107;
(III) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 86 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 74, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 108-117;
(IV) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 137 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 119, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 154-163; or
(V) the DNA-targeting segment comprises the sequence set forth in SEQ ID NO: 138 or the guide RNA target sequence comprises the sequence set forth in SEQ ID NO: 120, and wherein the ssODN comprises the nucleic acid sequence set forth in any one of SEQ ID NOS: 164-173.

### Claim 195

A genetically engineered human interleukin-2 receptor subunit gamma (IL2RG) protein comprising an artificial mutation to provide an altered epitope, wherein the altered epitope is a binding region of an IL2RG antagonist such that the IL2RG antagonist exhibits reduced or abolished ability to bind and/or inhibit the genetically engineered IL2RG protein compared to its ability to bind and/or inhibit a wild type human IL2RG protein, and wherein the genetically engineered IL2RG protein retains binding to its endogenous ligands.

### Claim 196 (depends on 195)

The genetically engineered human IL2RG protein of claim 195, wherein the genetically engineered IL2RG protein is functionally indistinguishable but immunologically distinguishable from a native IL2RG protein.

### Claim 197 (depends on 195, 196)

The genetically engineered human IL2RG protein of claim 195 or 196, wherein the altered epitope is in a binding region of the IL2RG antagonist, wherein the IL2RG antagonist is an antibody comprising an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 198 (depends on 195, 196, 197)

The genetically engineered human IL2RG protein of any one of claims 195-197, wherein the mutation comprises a mutation encoded by nucleotides within exon 2 and/or exon 3 of the IL2RG gene at the IL2RG genomic locus.

### Claim 199 (depends on 195, 196, 197, 198)

The genetically engineered human IL2RG protein of any one of claims 195-198, wherein the mutation comprises a mutation or substitution within a region from position T127 to position N150 and/or within a region from position L87 to position D97.

### Claim 200 (depends on 195, 196, 197, 198, 199)

The genetically engineered human IL2RG protein of any one of claims 195-199, wherein the artificial mutation comprises a mutation or substitution at position M145, position W90, position K92, position N93, position D95, position D97, position T127, position R139, position R140, position Q141, position T143, and/or position K147.

### Claim 201 (depends on 195, 196, 197, 198, 199, 200)

The genetically engineered human IL2RG protein of any one of claims 195-200, wherein the artificial mutation comprises a mutation or substitution at position M145, optionally wherein the substitution is a M145K substitution, a M145D substitution, a M145E substitution, a M145P substitution, a M145W substitution, or an M145Y substitution.

### Claim 202 (depends on 195, 196, 197, 198, 199, 200, 201)

The genetically engineered human IL2RG protein of any one of claims 195-201, wherein the artificial mutation comprises a M145K substitution.

### Claim 203 (depends on 195, 196, 197, 198, 199, 200, 201, 202)

The genetically engineered human IL2RG protein of any one of claims 195-202, wherein the mutation comprises a mutation or substitution at position W90, optionally wherein the substitution is a W90V substitution, a W90R substitution, a W90Q substitution, a W90L substitution, a W90K substitution, a W90E substitution, or a W90D substitution, optionally wherein the mutation comprises a W90Q substitution.

### Claim 204 (depends on 195, 196, 197, 198, 199, 200, 201, 202, 203)

The genetically engineered human IL2RG protein of any one of claims 195-203, wherein the mutation comprises a mutation or substitution at position M145 and a mutation or substitution at position W90.

### Claim 205 (depends on 195, 196, 197, 198, 199, 200, 201, 202, 203, 204)

The genetically engineered human IL2RG protein of any one of claims 195-204, wherein the genetically engineered IL2RG protein and the native IL2RG protein are functionally indistinguishable but immunologically distinguishable by the IL2RG antagonist.

### Claim 206 (depends on 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205)

The genetically engineered human IL2RG protein of any one of claims 195-205, wherein the IL2RG antagonist is an antigen-binding protein.

### Claim 207 (depends on 206)

The genetically engineered human IL2RG protein of claim 206, wherein the antigen-binding protein is an antibody or an antigen-binding fragment thereof.

### Claim 208 (depends on 206, 207)

The genetically engineered human IL2RG protein of claim 206 or 207, wherein the antigen-binding protein comprises an immunoglobulin light chain or variable region thereof comprising three light chain CDRs and an immunoglobulin heavy chain or variable region thereof comprising three heavy chain CDRs,
wherein the three light chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of sequences at least 90% identical to the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 209 (depends on 208)

The genetically engineered human IL2RG protein of claim 208, wherein the three light chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 12, 14, and 16, respectively, and
wherein the three heavy chain CDRs comprise, consist essentially of, or consist of the sequences set forth in SEQ ID NOS: 4, 6, and 8, respectively.

### Claim 210 (depends on 206, 207)

The genetically engineered human IL2RG protein of claim 206 or 207, wherein the antigen-binding protein comprises an immunoglobulin light chain variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 10, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain or variable region that comprises, consists essentially of, or consists of a sequence at least 90% identical to the sequence set forth in SEQ ID NO: 2.

### Claim 211 (depends on 210)

The genetically engineered human IL2RG protein of claim 210, wherein the immunoglobulin light chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 10, and
wherein the immunoglobulin heavy chain variable region comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 2.

### Claim 212 (depends on 206, 207)

The genetically engineered human IL2RG protein of claim 206 or 207, wherein the antigen-binding protein comprises an immunoglobulin light chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 20, and
wherein the antigen-binding protein comprises an immunoglobulin heavy chain that comprises, consists essentially of, or consists of the sequence set forth in SEQ ID NO: 18.

### Claim 213 (depends on 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212)

A nucleic acid encoding the genetically engineered human IL2RG protein of any one of claims 195-212, optionally wherein the nucleic acid is an expression vector encoding the genetically engineered human IL2RG protein.
